U.S. flag

An official website of the United States government

GTR Home > Tests > Hereditary Prostate Cancer Panel

Overview

Test order codeHelp: CDx009

Test name

Help

Hereditary Prostate Cancer Panel (Prostate Cancer)

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Predictive, Prognostic

Condition

Help

Click Indication tab for more information.

How to order

Help

Fill test requisition form and submit with saliva or buccal swab specimen
Order URL Help: http://claritidiagnostics.com/physicians/our-process/

Specimen source

Buccal swab
Isolated DNA
Saliva

Methodology

Help
Molecular Genetics
DDeletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • None/not applicable
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • illumina Miniseq
  • None/not applicable

Summary of what is tested

Click Methodology tab for more information.

Clinical utility

Help

Establish or confirm diagnosis

Predictive risk information for patient and/or family members

Lifestyle planning

Clinical validity

Help

99.99

Citations

Not provided

Test services

Help
  • Full gene sequencing and del/dup analysis

Suggested reading

Practice guidelines

  • HKUA/HKSU-O, 2022
    Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology
  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 4.2022
  • ASCO, 2021
    Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
  • ASCO, 2019
    Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
  • ACMG/NSGC, 2015
    A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
  • EGAPP, 2014
    Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
  • AUA, 2018
    Early detection of prostate cancer: AUA Guideline. (Reviewed and Confirmed, 2018)
  • NACB, 2008
    National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.